REG-4basebio UK Societas: Conversion to UK PLC

4BasebioAnnouncement

21/07/2021 07:05

21 July 2021

4basebio UK Societas

("4basebio" or the "Company")

Conversion to UK PLC

4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused
on exploiting intellectual property in the field of gene therapies and
vaccines, announces that it has completed its conversion from a UK Societas to
a public limited liability company registered in England and Wales (“PLC”)
(“Conversion”).

The Conversion was registered by Companies House as of 20 July 2021 and the
Company’s registration number was amended to: 13519889.

The Conversion was approved by 4basebio’s shareholders at the Annual General
Meeting of the Company held on 30 June 2021. Following completion of the
Conversion, the Company can proceed to conclude certain administrative matters
in relation to the Conversion (including any necessary updating in relation to
the change of name) which are expected to be completed on or around 29 July
2021. A further announcement will be made in due course.

For further enquiries, please contact:

 4basebio UK Societas                                         +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                            
                                                                                  
 Cairn Financial Advisers LLP (Nominated Adviser )            +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                                       
                                                                                  
 finnCap Ltd (Broker)                                         +44 (0)20 7220 0500 
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe                                  
                                                                                  
 Walbrook PR                       +44 (0)20 7933 8780 or 4basebio@walbrookpr.com 
 Anna Dunphy / Paul McManus        Mob: +44 (0)7876 741 001 / +44 (0)7980 541 893 
                                                                                  

Notes to Editors

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for gene therapies and DNA vaccines and providing solutions for effective
and safe delivery of these DNA based products to patients. It is the intention
of the Company to become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological use. The
immediate objectives of 4bb are to validate and scale its DNA synthesis and
advance its collaborations to facilitate the functional validation of its DNA
based products and gene delivery solutions.

The Company divested from 4basebio AG (“4bb AG”), a German company listed
on the Prime Standard segment of the Frankfurt Stock Exchange, following the
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology
business to AIM-quoted Abcam plc in January 2020 for €120million. Following
the disposal, 4bb AG retained its genomics business which owned and licensed
certain intellectual property including its proprietary, patent-protected
technology, TruePrime™. This is the foundation for building the Company’s
synthetic DNA manufacturing business which 4bb AG transferred to the Company
along with funding to continue the Company’s development and investment.



Copyright (c) 2021 PR Newswire Association,LLC. All Rights Reserved